Zentalis Pharmaceuticals, Inc. (ZNTL): Shareholders' Equity
$216.20M
As of 2025-12-31
$143.65M
As of 2026-06-30
-20.7%
3-year compound annual growth
-8.3%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $216.20M | -35.9% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $337.19M | -22.9% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $437.39M | +0.8% | 2026-03-26, Balance as of period end |
| 2022-12-31 | $434.02M | +19.1% | 2025-03-26, Balance as of period end |
| 2021-12-31 | $364.48M | +9.3% | 2024-02-27, Balance as of period end |
| 2020-12-31 | $333.38M | n/m | 2023-03-01, Balance as of period end |
| 2019-12-31 | -$73.28M | n/a | 2022-02-24, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | 2025-12-31 | $216.20M | -35.9% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare ZNTL, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗